Royal DSM has announced the availability of FUMzyme, fumonisin esterase, for use in poultry and swine feed in the United States. FUMzyme is the first-ever FDA-approved purified enzyme to specifically and irreversibly degrade fumonisins into non-toxic metabolites. DSM received FDA approval of the novel enzyme in June (swine) and August (poultry) of 2022.
"With each year's crop we see variation in mycotoxin contamination patterns," said Paige Gott, DSM mycotoxin and Hy•D category manager. "Fumonisin is one mycotoxin that continues to show high prevalence across the United States. In fact, since 2014, this mycotoxin has been detected in 50% to 80% of corn samples screened as part DSM's annual mycotoxin survey."
DSM is introducing FUMzyme as part of the Biofix product portfolio. The two new products, Biofix Plus with FUMzyme and Biofix Select with FUMzyme, will be available mid-November 2022 for both swine and poultry.
"Because of the various negative outcomes on livestock health and performance associated with mycotoxins, it's important for producers to take proactive steps to mitigate mycotoxins on-farm," said Gott. "FUMzyme is a new tool that producers can incorporate as part of a comprehensive mycotoxin risk management strategy."
Source: DSM, which is solely responsible for the information provided, and wholly owns the information. Informa Business Media and all its subsidiaries are not responsible for any of the content contained in this information asset.